Orexigen Therapeutics Newswire

Orexigen Therapeutics Newswire

Comprehensive Real-Time News Feed for Orexigen Therapeutics.

Results 1 - 20 of 62 in Orexigen Therapeutics

  1. Orexigen Therapeutics (OREX) Given New $0.02 Price Target at S&P Equity ResearchRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    S&P Equity Research's target price points to a potential downside of 91.03% from the company's current price. Shares of Orexigen Therapeutics stock traded down $0.12 during trading on Wednesday, reaching $0.22.

    Comment?

  2. Pernix Wins Auction; Orexigen's Sale Of Contrave Looks To Be CompleteRead the original story w/Photo

    Jun 27, 2018 | Seeking Alpha

    Orexigen Therapeutics will soon be no more. After filing for bankruptcy and placing itself on the auction block, a sole bidder, Nalproprion Pharmaceuticals, has been declared the winner and will acquire essentially all assets and some limited liabilities for a sum of $75 million.

    Comment?

  3. Somewhat Positive Press Coverage Somewhat Unlikely to Impact Orexigen Therapeutics (OREX) Share PriceRead the original story w/Photo

    Jun 8, 2018 | Daily Political

    Press coverage about Orexigen Therapeutics has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  4. Somewhat Positive Media Coverage Somewhat Unlikely to Affect Orexigen Therapeutics (OREX) Stock PriceRead the original story w/Photo

    May 29, 2018 | Daily Political

    News headlines about Orexigen Therapeutics have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time.

    Comment?

  5. Orexigen Therapeutics (OREX) Earns News Impact Score of 0.04Read the original story w/Photo

    May 19, 2018 | IntersportsWire

    News coverage about Orexigen Therapeutics has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  6. Orexigen Therapeutics (OREX) Given Daily Coverage Optimism Score of 0.04Read the original story w/Photo

    May 14, 2018 | IntersportsWire

    News stories about Orexigen Therapeutics have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time.

    Comment?

  7. Anti-Obesity Prescription Drugs Market: Global Industry Analysis,...Read the original story

    May 10, 2018 | Emailwire.com

    ... and market share for each manufacturer, covering o F Hoffmann La Roche o Arena Pharmaceuticals o Orexigen Therapeutics o Phentermine and Topiramate o VIVUS, Inc o Liraglutide o Bupropion and Naltrexone o Orlistat o Bupropion and Naltrexone o Novo ...

    Comment?

  8. Orexigen Therapeutics (OREX) Given Daily News Impact Rating of 0.00Read the original story w/Photo

    May 9, 2018 | Daily Political

    News coverage about Orexigen Therapeutics has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time.

    Comment?

  9. Orexigen Therapeutics (OREX) Receiving Somewhat Positive Media Coverage, Study ShowsRead the original story w/Photo

    Apr 29, 2018 | IntersportsWire

    News coverage about Orexigen Therapeutics has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources.

    Comment?

  10. Seth Klarman Dives Into Orexigen in Wake of SaleRead the original story w/Photo

    Apr 27, 2018 | GuruFocus.com

    Baupost Group's Seth Klarman disclosed this week he plunged into floundering pharmaceutical company Orexigen Therapeutics Inc. on April 13, buying over 7 million shares. Klarman, whose investments range from traditional value plays to distressed debt and liquidations, boosted his stake in the San Diego-based company, which focuses on weight loss and obesity, for an average price of 22 cents per share.

    Comment?

  11. Somewhat Favorable Media Coverage Somewhat Unlikely to Impact...Read the original story w/Photo

    Apr 24, 2018 | IntersportsWire

    Complete the form below to receive the latest headlines and analysts' recommendations for Orexigen Therapeutics with our free daily email newsletter:

    Comment?

  12. Orexigen Therapeutics (OREX) Receives News Impact Rating of 0.07Read the original story w/Photo

    Apr 19, 2018 | IntersportsWire

    News articles about Orexigen Therapeutics have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time.

    Comment?

  13. Analysts See $-0.18 EPS for Affimed N.V. (AFMD); Orexigen Therapeutics (OREX) Shorts Lowered By 4.38%Read the original story w/Photo

    Apr 18, 2018 | Hill Country Times

    ... declined 25.96% since April 18, 2017 and is downtrending. It has underperformed by 37.51% the S&P500. Orexigen Therapeutics Inc (NASDAQ:OREX) had a decrease of 4.38% in short interest. OREX's SI was 709,300 shares in April as released by FINRA. Its ...

    Comment?

  14. Orexigen Therapeutics (OREX) Given News Sentiment Rating of -0.11Read the original story w/Photo

    Apr 4, 2018 | Daily Political

    Media headlines about Orexigen Therapeutics have been trending somewhat negative on Wednesday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time.

    Comment?

  15. Orexigen Therapeutics, Inc. (OREX) Sees Significant Drop in Short InterestRead the original story w/Photo

    Mar 31, 2018 | Daily Political

    Orexigen Therapeutics, Inc. was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 741,785 shares, a decline of 34.7% from the February 28th total of 1,135,890 shares.

    Comment?

  16. Orexigen Therapeutics, Inc. (OREX) Short Interest Down 34.7% in MarchRead the original story w/Photo

    Mar 30, 2018 | AmericanBankingNews.com

    Orexigen Therapeutics, Inc. was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 741,785 shares, a decrease of 34.7% from the February 28th total of 1,135,890 shares.

    Comment?

  17. Orexigen Therapeutics (OREX) Receiving Somewhat Negative News Coverage, Accern ReportsRead the original story w/Photo

    Mar 30, 2018 | IntersportsWire

    Headlines about Orexigen Therapeutics have been trending somewhat negative recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time.

    Comment?

  18. Orexigen Therapeutics (OREX) Shares Up 5%Read the original story w/Photo

    Mar 30, 2018 | The Breeze

    Shares of Orexigen Therapeutics, Inc. shot up 5% on Friday . The company traded as high as $0.23 and last traded at $0.21.

    Comment?

  19. Orexigen Therapeutics (OREX) Receives Daily News Impact Rating of -0.14Read the original story w/Photo

    Mar 25, 2018 | The Breeze

    News headlines about Orexigen Therapeutics have trended somewhat negative this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources.

    Comment?

  20. Orexigen Therapeutics (OREX) Hits New 52-Week Low at $0.22Read the original story w/Photo

    Mar 24, 2018 | Daily Political

    Shares of Orexigen Therapeutics, Inc. hit a new 52-week low on Thursday . The company traded as low as $0.22 and last traded at $0.22, with a volume of 463347 shares changing hands.

    Comment?